Search
Zag Bio launched today with $80M, and aims to tackle autoimmune disease by using antibodies to reprogram how Tregs and Teffs are created in the thymus. The lead indication will be Type 1 diabetes.
CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D program is scheduled to be in the clinic by late 2026.
Oct 28
SalioGen’s CEO on the company’s ‘Gene Coding’ approach to genetic medicine and an oral presentation today at #ASGCT2024 for its Stargardt disease program
Jason Cole describes how Gene Coding can deliver large sequences to the genome without viral vectors or RNA guides, and describes how...
May 7, 2024
.png){kind=logo}
